Compare DexCom, Inc. (DXCM) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Snap On Incorporated — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Snap On Incorporated trades at $361.38 (market cap $18.56B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Snap On Incorporated pays a 2.72% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Snap On Incorporated for 37 Days on average.
| DXCM | SNA | |
|---|---|---|
Market Cap | $31.86B | $18.56B |
Volume | 3,607,070 | 401,326 |
Sector | Health | Industrials |
52-Week High | $92.34 | $419.31 |
52-Week Low | $54.84 | $327.33 |
Typical Hold Time | 62 Days | 37 Days |
Enterprise Value | $31.32B | $18.20B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
Snap-On Incorporated (SNA) trades at $360.37, up 0.13% on the day, with a bearish technical outlook but strong fundamentals. The stock shows robust profitability with a 19.6% net income margin and 17.58% ROE, supported by consistent earnings beats in recent quarters. Analyst consensus is bullish with a $449 price target, though technical indicators signal selling pressure near key resistance at $361.
SNA presents a compelling investment case driven by solid earnings growth and expanding margins, but faces near-term technical headwinds and valuation risks. The stock's premium P/E of 18.31 may limit upside if growth moderates, while institutional activity shows mixed positioning. Investors should weigh strong cash flow against competitive pressures in the tools sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
